AUTL News and Press, Autolus Therapeutics plc From 09/15/21

LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Direc...

- Goldman Sachs Eleventh Annual Biotech Symposium on September 7 - 2021 Virtual Wells Fargo Healthcare Conference on September 10 at 7.30am ET - H.C. Wainwright & Co 23rd Annual Global Investment Conference on September 13, at 7.00am ET LONDON, Sept. ...

LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced publication of the obecabtagene autoleucel (obe-cel) Phase 1 ALLCAR19 data in Jour...

LONDON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received Promising Innovative Medicine (PIM) designation from the UK Medicin...

The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2021 Q2 earnings call. For further details see: Autolus Therapeutics plc 2021 Q2 - Results - Earnings Call Presentation

Autolus Therapeutics (NASDAQ:AUTL): Q2 GAAP EPS of -$0.47 beats by $0.04. Revenue of $1.6M (+451.7% Y/Y) beats by $1.41M. Cash at June 30, 2021, totaled $216.4 million, as compared to $239.0 million at March 31, 2020.  Press Release For further details see...

LONDON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the quarter ended June 30, 2021. “...

Shares of Autolus Therapeutics (NASDAQ: AUTL) , a clinical-stage biopharmaceutical company, are on the move after the company announced a new deal with Moderna (NASDAQ: MRNA) . Investors excited about Autolus Therapeutics' potential role in Moderna's commercialization of RNA...

Ever-Glory EVK +75% announces $5 million share buyback plan Exicure (NASDAQ:XCUR) +36% and Ipsen enter into exclusive collaboration targeting rare neurodegenerative disorders AgriFORCE (AGRI) +20%. Autolus Therapeutics (NASDAQ:AUTL) +18%. and Moderna sign Option and License Agr...

LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced an agreement with Moderna, a biotechnology company pioneering messenger RNA (mRNA) thera...